Acquisition strengthens P&F’s structural heart portfolio with the addition of the AngelValve™ Augmentation System, a novel transcatheter solution for mitral regurgitation, further expanding the company’s portfolio of next-generation transcatheter heart valve therapies and reinforcing its long-term commitment to structural heart innovation. Vienna, Austria, Aug. 5,
P&F secures CE Mark Certification under the EU Medical Device Regulation (MDR) 2017/745 regulations for TricValve® Bicaval Valve System, A Breakthrough Minimally Invasive Therapy for Severe Tricuspid Regurgitation Vienna, Austria, Feb. 5, 2026 — P&F Products and Features GmbH, a global heart valve MedTech company
TRICAV II will evaluate the safety and effectiveness of the TricValve® Transcatheter Bicaval Valve System Wilmington, Delaware, Dec. 12, 2025 — P&F USA, Inc., the U.S. subsidiary of global heart valve manufacturer P&F Products and Features GmbH, today announced that the U.S. Food and Drug
